VarmX
The company develops VMX-C001, a swift-acting universal bypassing agent designed to restore blood coagulation in patients taking Factor Xa Direct Oral Anticoagulants (FXa-DOACs). This therapeutic protein aims to stop severe bleeding and minimize bleeding risks during surgical procedures. The product is intended for medical professionals treating patients who require immediate reversal of anticoagulant effects.
Visit websiteLeiden, Netherlands
Biotechnology
Healthcare
Pharmaceuticals
Funding summary
- Total raised
- €47.5M
- Funding rounds
- 2
Investors in VarmX
Investors on record for VarmX. Click any investor to view their CAPLINK profile and funding criteria.
Fundraising for a startup like VarmX?
Explore CAPLINK's investor database of thousands of active VCs and angels.
Browse investors